Inspired by, Original post: https://lnkd.in/g596veqc
As the U.S. regulatory landscape becomes increasingly complex for novel neurotechnologies, early-stage startups are exploring Europe for their clinical trials. The European Clinical Trials Regulation (CTR) has introduced harmonized and streamlined processes, making trial approvals faster and more predictable.
The €66.8M READI initiative is investing in trial readiness and diversity across the EU. Spain, for instance, has seen a significant increase in trial activity due to proactive infrastructure investments.
This shift presents both challenges and opportunities. While Europe aims to attract more trials by addressing existing bottlenecks, startups must navigate the evolving landscape to capitalize on these developments.
Let's talk about it! What are your thoughts?
NeuroTech ClinicalTrials MedTech StartupFunding Chaanakyacapital HealthcareInnovation EUHealth RegulatoryStrategy AIinHealth VC venturecapital angelinvesotor investment founder
Add comment
Comments